You are required to be logged in to access the full website
Click here if you have forgotten your username or password
Therapy Areas
28 November 2025 - Swedish pharmaceutical company Immedica Pharma AB said on Friday that the Zepzelca (lurbinectedin) + Tecentriq (atezolizumab) maintenance regimen is now approved by the Emirates Drug Establishment for adults in the United Arab Emir...
28 November 2025 - Beyond Pink welcomed healthcare professionals, cancer survivors and community figures for an evening focused on wellness, awareness and preventative care for women. Taking place at the Grand Hyatt Dubai, the event began with a netw...
28 November 2025 - Imugene Ltd (ASX:IMU), an Australian clinical-stage immuno-oncology company, announced on Thursday that it has entered a co-development collaboration with JW Therapeutics (Shanghai) Co., LTD (HKEX:2126), a Chinese biotechnology com...
28 November 2025 - Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKEX: 6990), a China-based holding subsidiary of Kelun Pharmaceutical (002422.SZ), announced on Thursday that the journal of Annals of Oncology (Impact Factor: 65.4) has published ...
28 November 2025 - * Evidence-based digital care and medication-assisted treatment now offered across the state through a mobile app.Workit Health, recognised as one of the United States' most trusted online providers for substance use treatment...
27 November 2025 - Chinese biopharmaceutical company Gan & Lee Pharmaceuticals Co., Ltd. (SHA: 603087) announced on Thursday that it has begun GRADUAL-3, its third large-scale phase 3 study of the GLP-1 receptor agonist bofanglutide (GZR18) in ov...
27 November 2025 - Swedish biopharmaceutical company Mendus AB (STO:IMMU) on Thursday reported positive two-year follow-up data from the ALISON Phase 1 trial, confirming the safety, tolerability and feasibility of vididencel as an active immunotherap...